Analyst Upgrades

• Siemens (SI) to buy from hold at Deutsche Bank.
• Diamond Offshore (DO) to market perform from underperform at FBR Capital.
• MeadWestvaco (MWV) to conviction buy from neutral at Goldman.
• TD AmeriTrade (AMTD) and Cabot Oil & Gas (COG) to buy from neutral at BofA/Merrill.
• Janus Capital (JNS) to hold from sell at Citigroup.
• Motorola Mobility (MMI) to buy from neutral at UBS.
• Frontier Communications (FTR) to neutral from underperform at Macquarie.
• Humana (HUM) to buy from hold at Argus.

Analyst Upgrades

• General Growth (GGP) to outperform from neutral at Credit Suisse.
• PPL Corp. (PPL) to outperform from market perform at FBR Capital.
• Hudson City Bancorp (HCBK) to neutral from reduce at Nomura.
• Hologic (HOLX) to conviction buy from buy at Goldman.
• Cognex (CGNX) to overweight from neutral at Piper Jaffray.
• Buckeye Partners (BPL) to outperform from market perform at Wells Fargo.
• Ericsson (ERIC) and Health Care REIT (HCN) to buy from neutral and Olin (OLN) to neutral from sell at UBS.
• Nalco (NLC) to overweight from neutral at JPMorgan.
• Watts Water (WTS) to buy from hold at BB&T.
• McDermott (MDR) to buy from neutral at Pritchard.

Analyst Upgrades

• inContact (SAAS) to buy from neutral at Roth Capital.

Analyst Downgrades

• Ericsson (ERIC) to neutral from buy at Goldman.
• Hovnanian (HOV) to underperform from buy at BofA/Merrill.
• PrivateBancorp (PVTB) to market perform from outperform at BMO Capital.
• Logitech (LOGI) to neutral from outperform at Exane BNP Paribas.

Allergan (AGN - option chain) shares are rising today after the company announced FDA approval of Allergan's Botox for use as a treatment for chronic Migraine headaches on Friday after the close of trading. This opens an entirely new market for that drug, which was almost exclusively used for cosmetic purposes. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AGN.

AGN opened this morning at $71.97. So far today the stock has hit a low of $71.14 and a high of $72.56. As of 12:10, AGN is trading at $72.43 up $3.57 (5.2%). The chart for AGN looks bullish and S&P gives AGN a positive 4 STARS (out of 5) buy ranking.

As the opening bell sounded and stocks got off to a sluggish start, I decided to take a look for stocks that got off to a fast start. One of those stocks is Botox-maker Allergan (AGN). In early trading, the pharmaceutical firm was more than a percentage point higher, so I took to digging to find out why.

The biggest news I found for Allergan was that it entered into an Amended and Restated License, Development and Marketing Agreement with Inspire Pharmaceuticals. The agreement deals with terms related to the Prolacria 2% development program and Inspire's right to receive revenues from Allergan relating to net sales of Restasis and any other human opthalmic formulations of cyclosporine owned or controlled by Allergan. Simply put, Inspire will receive revenues on net sales of Restasis and any related cyclosporine-based medicines.

Drug manufacturer Allergan, Inc. (AGN) will be reporting its second quarter results on Monday, with analysts expecting to see an 8% earnings increase from the same period last year.

Analysts have forecast earnings of $0.81 for the quarter, versus $0.75 during the same period last year.

Allergan has managed to outpace analyst estimates for each of the past six quarters, and has not failed to at least match estimates since the first quarter of 2007.

Analyst upgrades:

• Morgan Keegan upgraded Copano Energy (CPNO) to Outperform from Market Perform based on the $300M capital infusion it received from TPG Capital.
• Wells Fargo upgraded SunTrust (STI) to Market Perform from Underperform following the company's Q2 results citing improving credit quality trends and valuation.
• UBS upgraded Baidu (BIDU) to Buy from Neutral based on solid fundamentals following the strong Q2 report and guidance and valuation. The firm raised its price target to $92 from $69.
• Baxter (BAX) was upgraded to Conviction Buy from Neutral at Goldman.
• JetBlue (JBLU) was upgraded to Buy from Hold at Soleil.
• Penn Virginia GP (PVG) was upgraded to Outperform from Sector Perform at RBC Capital.

Analyst downgrades:

• Piper Jaffray downgraded Beckman Coulter (BEC) to Neutral from Overweight following the company's weaker than expected Q2 results and lowered guidance. The firm lowered its target for shares to $60 from $74. Shares were also downgraded to Hold from Buy at Jefferies and to Neutral from outperform at Baird following the company's reduced guidance.
• Keefe Bruyette cut AmeriCredit (ACF) to Market Perform from Outperform following the acquisition by General Motors (GM, MTLQQ).
• FBR Capital downgraded SunTrust (STI) to Market Perform from Outperform and lowered its price target to $27 from $34. The analyst believes larger banks are better positioned than regionals due to greater prospects of reserve releases.
• Travelers (TRV) was downgraded to Perform from Outperform at Oppenheimer.
• Lender Processing (LPS) was downgraded to Neutral from Buy at Goldman.
• Penn Virginia Resource (PVR) was downgraded to Sector Perform at RBC Capital.

Analyst initiations:

• ThinkEquity assumed coverage of SanDisk (SNDK) with a Buy rating.
• Macquarie initiated Allergan (AGN) with an Outperform rating and $75 price target.
• Macquarie also initiated Cooper Companies (COO) with an Outperform rating and $45 price target.
• NCR Corp (NCR) was initiated with a Hold rating at KeyBanc.
• CryoLife (CRY) was started at Benchmark Co. with a Buy rating and $8 target.
• China New Borun (BORN) was initiated with an Overweight rating and $7.40 target at Piper Jaffray.

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

It appears that U.S.-based drug makers and cigarette companies caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot Friday:

Analyst Upgrades

• JPMorgan upgraded T. Rowe Price (TROW) to overweight from neutral while downgrading Janus Capital (JNS) to underweight from neutral to reflect valuations and fundamentals. The firm has a $67 price target for T. Rowe Price shares.
• Piper Jaffray upgraded Lincoln Electric (LECO) to overweight from neutral as it believes the rebound in global manufacturing is accelerating. The firm has a $70 price target on the stock.
• Wells Fargo upgraded Highwoods Properties (HIW) to market perform from underperform, citing valuation and a strong balance sheet.
• Corning (GLW) was upgraded to outperform from sector perform at RBC Capital.
• Allergan (AGN) was upgraded to conviction buy from neutral at Goldman.
• Mohawk (MHK) was upgraded to buy from neutral at SunTrust.

Allergan (AGN - option chain) shares are rising today after the FDA approved Allergan's drug Botox for treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AGN.

AGN opened this morning at $62.60. So far today the stock has hit a low of $61.90 and a high of $62.78. As of 12:00, AGN is trading at $62.42 up $1.07 (1.7%). The chart for AGN looks neutral and S&P gives AGN a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• JPMorgan upgraded TiVo (TIVO) to overweight from neutral as it believes Thursday's appeal win against DISH Network could lead to revenue upside. The firm raised its target price for shares to $23 from $15.
• Collins Stewart upgraded DISH Network (DISH) to buy from hold on valuation, as it believes much of the impact from the negative appeals ruling is priced into the stock. The firm has a $30 target for shares.
• Cowen upgraded Ciena (CIEN) to outperform from neutral. The firm believes Ciena's acquisition of MEN is transformative and will accelerate top line growth.
• Progress Software (PRGS) was upgraded to buy from hold at Needham.
• Allergan (AGN) was upgraded to buy from hold at Lazard Capital.
• Public Service (PEG) was upgraded to buy from hold at Jefferies.

Analyst Upgrades

• Keefe Bruyette upgraded MSCI Inc. (MXB) to outperform from market perform on valuation following Monday's sell-off as it views the acquisition of RiskMetrics (RISK) favorably. The firm has a $36 price target on shares. UBS also upgraded MSCI, to buy from neutral, and raised its target to $40 from $34, citing the recent pullback in shares and the accretive acquisition of RiskMetrics.
• Deutsche Bank upgraded Suncor (SU) to hold from sell on valuation and raised its price target on shares to $28 from $20. The firm continues to prefer Canadian Natural (CNQ) to Suncor, however, and raised its target on shares to $80 from $78.
• JMP Securities upgraded Grubb & Ellis (GBE) to outperform from market perform based on the improved operating environment and balance sheet, and valuation, among other reasons.
• Dell (DELL) was upgraded to buy from neutral at UBS.
• FEMSA (FMX) was upgraded to overweight from neutral at HSBC.
• Westar Energy (WR) was upgraded to outperform from market perform at Wells Fargo.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher.
• Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher.
• Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged.
• Cabot Oil & Gas Corp. (NYSE: COG) received an upgrade following the release of its Q3 numbers.
• Estee Lauder Companies Inc. (NYSE: EL) reported strong Q1 results, sending shares higher.
• E*Trade Financial Corp. (NASDAQ: ETFC) reported a smaller-than-expected net loss for Q3.
• Goodyear Tire & Rubber Co. (NYSE: GT) Q3 earnings topped estimates and revenue was up sequentially.

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.

On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cents -- 5 cents higher than the average estimate of analysts polled by Thomson Reuters I/B/E/S. It seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010.